SAN DIEGO and CARLSBAD, Calif., July
24, 2012 /PRNewswire/ -- Gen-Probe Incorporated (NASDAQ:
GPRO) and Life Technologies Corporation (NASDAQ: LIFE) today
announced they have signed a distribution agreement for
SeCore® HLA Sequence-Based Typing (SBT) kits for use
with Life Technologies' 3500 Dx Genetic Analyzer.
(Logo: http://photos.prnewswire.com/prnh/20120312/LA68580LOGO)
Under the terms of the agreement, Gen-Probe's LIFECODES unit
will have co-exclusive rights to sell SeCore SBT products into the
transplant market alongside Life Technologies' dedicated HLA sales
force in the United States. LIFECODES will initiate sales of
the SeCore HLA SBT line this month. Financial terms of the
agreement were not disclosed.
"We are excited to work with the Life Technologies team to bring
to market testing products that can help improve transplant
science," said Shawn Marcell,
General Manager of LIFECODES. "With the growing importance of
sequencing in transplant diagnostics, the SeCore HLA SBT product
line will play a significant role in future growth by rounding out
our product portfolio with one of the highest resolution offerings
in molecular typing."
"This relationship was established to offer customers greater
flexibility and access to high-resolution typing solutions with
efficient workflows. SeCore forms the basis for 100%
resolution in molecular typing for HLA today," said Todd Laird, General Manager of Life
Technologies' transplant diagnostics business.
The distribution agreement follows a supply and collaboration
agreement between the companies announced in May 2011.
SeCore HLA SBT kits are Life Technologies' latest line of
high-resolution human leukocyte antigen (HLA) typing products based
on sequence-based typing, the 'gold standard' of allele
identification. SeCore HLA SBT kits are designed for ease of
use and yield high quality results.
These products are available as Research Use Only. They are not
cleared for diagnostic use.
About Gen-Probe
Gen-Probe is a global leader in the development, manufacture and
marketing of rapid, accurate and cost-effective molecular
diagnostic products and services that are used primarily to
diagnose human diseases, screen donated human blood, and ensure
transplant compatibility. Gen-Probe is headquartered in
San Diego and employs
approximately 1,400 people. For more information, go to
http://www.gen-probe.com.
About LIFECODES
LIFECODES is a wholly owned business of Gen-Probe and a leader
in the development, manufacture and marketing of cutting edge
assays to facilitate the process of matching organ donations with
patients requiring organ transplants. LIFECODES is based in
Stamford, CT and Waukesha, WI and does business in over 75
countries throughout the world.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global
biotechnology company with customers in more than 160 countries
using its innovative solutions to solve some of today's most
difficult scientific challenges. Quality and innovation are
accessible to every lab with its reliable and easy-to-use solutions
spanning the biological spectrum with more than 50,000 products for
agricultural biotechnology, translational research, molecular
medicine and diagnostics, stem cell-based therapies, forensics,
food safety and animal health. Its systems, reagents and
consumables represent some of the most cited brands in scientific
research including: Ion Torrent™, Applied
Biosystems®, Invitrogen™, GIBCO®,
Ambion®, Molecular Probes®,
Novex®, and TaqMan®. Life Technologies
employs approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive
licenses. LIFE had sales of $3.7
billion in 2011. Visit us at our website:
http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and
uncertainties. Some of the information contained in this press
release, including, but not limited to, statements as to industry
trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that
are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or
implied by such forward-looking statements. Any statements that are
not statements of historical fact are forward-looking statements.
When used, the words "believe," "plan," "intend," "anticipate,"
"target," "estimate," "expect" and the like, and/or future tense or
conditional constructions ("will," "may," "could," "should," etc.),
or similar expressions, identify certain of these forward-looking
statements. Important factors which could cause actual results to
differ materially from those in the forward-looking statements are
detailed in filings made by Life Technologies with the
Securities and Exchange Commission. Life Technologies
undertakes no obligation to update or revise any such
forward-looking statements to reflect subsequent events or
circumstances.
Gen-Probe Caution Regarding Forward-Looking
Statements
Any statements in this news release about Gen-Probe's
expectations, beliefs, plans, objectives, assumptions or future
events or performance of Gen-Probe are forward-looking
statements. These statements are often made through the use
of words or phrases such as believe, will, expect, anticipate,
estimate, intend, plan and would. For example, statements
concerning possible or expected results of operations, regulatory
approvals, the development and commercialization of new products,
future sales and product menu offerings, growth opportunities, and
plans of management are all forward-looking statements.
Forward-looking statements are not guarantees of performance.
They involve known and unknown risks, uncertainties and assumptions
that may cause actual results to differ materially from those
expressed or implied. Some of these risks include: (i) the
risk that the distribution agreement will not result in significant
SeCore HLA SBT product sales; (ii) the risk that the companies may
not succeed in achieving the goals they each anticipate in
connection with the distribution agreement, and (iii) the risk that
Gen-Probe may not be able to compete effectively in the transplant
diagnostics market. This list includes some, but not all, of
the factors that could affect the ability of Gen-Probe to achieve
results described in any forward-looking statements. For
additional information about risks and uncertainties Gen-Probe
faces and a discussion of financial statements and related
footnotes, see documents Gen-Probe files with the SEC.
Gen-Probe assumes no obligation and expressly disclaims any duty to
update forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect the
occurrence of subsequent events.
Contacts:
|
|
Al
Kildani
|
Suzanne
Clancy
|
Sr.
director, investor relations and
|
Life
Technologies Corporation
|
corporate
communications
|
760-717-8294
|
Gen-Probe,
Incorporated
|
Suzanne.clancy@lifetech.com
|
858-410-8653
|
|
SOURCE Gen-Probe Incorporated